Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NLRP3 | Q96P20 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | ESR1 | P03372 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8887419 | 1.00 | NLRP3 (0.36) | NLRP3ALDH1A1LMNAHSD17B10ESR1 | |
| SCHEMBL8610759 | 1.00 | NLRP3 (0.36) | NLRP3ALDH1A1LMNAHSD17B10ESR1 | |
| SCHEMBL6664774 | 0.92 | NLRP3 (0.40) | NLRP3ALDH1A1LMNAHSD17B10 | |
| SCHEMBL6664770 | 0.92 | NLRP3 (0.40) | NLRP3ALDH1A1LMNAHSD17B10 | |
| SCHEMBL8887856 | 0.83 | NLRP3 (0.35) | NLRP3ALDH1A1LMNAHSD17B10 | |
| SCHEMBL8887855 | 0.83 | NLRP3 (0.35) | NLRP3ALDH1A1LMNAHSD17B10 | |
| SCHEMBL20658771 | 0.78 | ALDH1A1 (0.37) | NLRP3ALDH1A1LMNAHSD17B10 | |
| SCHEMBL22666432 | 0.78 | ALDH1A1 (0.37) | NLRP3ALDH1A1LMNAHSD17B10 | |
| SCHEMBL22666168 | 0.78 | ALDH1A1 (0.37) | NLRP3ALDH1A1LMNAHSD17B10 | |
| SCHEMBL20859716 | 0.78 | ALDH1A1 (0.37) | NLRP3ALDH1A1LMNAHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230136594-A1 | TRICYCLIC P2-LIGAND CONTAINING POTENT HIV-PROTEASE INHIBITORS | PURDUE RESEARCH FOUNDATION | 2023-05-04 | — | — | US | disclosed |
| US-20230136594-A1 | TRICYCLIC P2-LIGAND CONTAINING POTENT HIV-PROTEASE INHIBITORS | PURDUE RESEARCH FOUNDATION | 2023-05-04 | — | — | US | disclosed |
| US-20230136594-A1 | TRICYCLIC P2-LIGAND CONTAINING POTENT HIV-PROTEASE INHIBITORS | PURDUE RESEARCH FOUNDATION | 2023-05-04 | — | — | US | disclosed |
| WO-2021188191-A1 | TRICYCLIC P2-LIGAND CONTAINING POTENT HIV-PROTEASE INHIBITORS | PURDUE RESEARCH FOUNDATION (US) | 2021-09-23 | — | — | WO | disclosed |
| US-5663175-A | THYMIDINE KINASE | MERCK & CO. INC. (US) | 1997-09-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230136594-A1 | TRICYCLIC P2-LIGAND CONTAINING POTENT HIV-PROTEASE INHIBITORS | CD4, P2RY1, P2RX7 | NLRP3 537/4885ALDH1A1 2720/4885LMNA 2969/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.